For example, a 15-bp double-stranded decoy oligonucleotide, targeting the STAT3 response element in the Finkel-Biskis-Jinkins murine osteogenic sarcoma, FOS promoter, was shown to competitively inhibit STAT3 binding to DNA and to suppress tumor growth in preclinical models of different types of solid cancers [19,20]. The gene discussed is STAT3; the disease is neoplasm.